Methotrexate-induced pulmonary fibrosis in a patient with psoriasis

Authors

  • Germán Gastón Mangiarotti Eva Perón Acute General Hospital, San Martín, Province of Buenos Aires, Argentina https://orcid.org/0000-0002-8777-0889
  • Cintia Marisol Arias Eva Perón Acute General Hospital, San Martín, Province of Buenos Aires, Argentina
  • Lindsay Quiñones Eva Perón Acute General Hospital, San Martín, Province of Buenos Aires, Argentina
  • Gimena Antonia Castro Pérez Eva Perón Acute General Hospital, San Martín, Province of Buenos Aires, Argentina

DOI:

https://doi.org/10.47196/da.v27i2.2049

Keywords:

methotrexate, pulmonary fibrosis, psoriasis

Abstract

Pulmonary fibrosis due to methotrexate is an infrequent adverse event, observed mainly in patients with rheumatoid arthritis, although it has also been poorly described in the treatment of psoriasis. We present the case of a patient with psoriasis who developed pulmonary fibrosis due to methotrexate.

Author Biographies

Germán Gastón Mangiarotti, Eva Perón Acute General Hospital, San Martín, Province of Buenos Aires, Argentina

Medical Doctor. Dermatology Specialist

Cintia Marisol Arias, Eva Perón Acute General Hospital, San Martín, Province of Buenos Aires, Argentina

Staff Medical Doctor. Dermatology Specialist

Lindsay Quiñones, Eva Perón Acute General Hospital, San Martín, Province of Buenos Aires, Argentina

Medical Doctor. Diagnostic Imaging Specialist

Gimena Antonia Castro Pérez, Eva Perón Acute General Hospital, San Martín, Province of Buenos Aires, Argentina

Head of the Dermatology Service

References

I. Amatore F, Villani AP, Tauber M, et ál. French guidelines on the use of systemic treatments for moderate to severe psoriasis in adults. J Eur Acad Dermatol Venereol. 2019;33:464-483.

II. Lavieri A, Acevedo A, Baccarini E, et ál. Consenso nacional de psoriasis. Sociedad Argentina de Dermatología 2020 [en línea]. Disponible en: https://sad.org.ar/wp-content/uploads/2020/09/CONSENSO-NACIONAL-DE-PSORIASIS.-ACTUALIZACION-2020.-.pdf [Consultado septiembre 2020].

III. Igualada Quintanilla J, Romero Candel G, Tejada Cifuentes F. Metotrexato: toxicidad pulmonar, hepática y hematológica. Rev Clin Med Fam. 2016;9:159-166.

IV. Alarcón GS, Kremer JM, Macaluso M, et ál. Risk factors for methotrexate induced lung injury in patients with rheumatoid arthritis. Ann Intern Med. 1997;127:356-364.

V. Lateef O, Shakoor N, Balk RA. Methotrexate pulmonary toxicity. Expert Opin Drug Saf. 2005;4:723-730.

VI. Wang W, Zhou H, Liu L. Side effect of methotrexate therapy for rheumatoid arthritis: A systematic review. Eur J Med Chem 2018;158:502-516.

VII. Kim YJ, Song M, Ryu JC. Mechanisms underlying methotrexate induced pulmonary toxicity. Expert Opin Drug Saf 2009;8:451-458.

VIII. Gurczynski SJ, Moore BB. IL-17 in the lung: the good, the bad and the ugly. Am J Physiol Lung Cell Mol Physiol 2018; 314:L6–L16.

Revista Dermatología Argentina Nº 2 de 2021

Downloads

Published

2021-06-30

Issue

Vol. 27 No. 2 (2021): April-June 2021

Section

Clinical Cases

License

Copyright (c) 2021 Dermatología Argentina

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

El/los autor/es tranfieren todos los derechos de autor del manuscrito arriba mencionado a Dermatología Argentina en el caso de que el trabajo sea publicado. El/los autor/es declaran que el artículo es original, que no infringe ningún derecho de propiedad intelectual u otros derechos de terceros, que no se encuentra bajo consideración de otra revista y que no ha sido previamente publicado.

 

Le solicitamos haga click aquí para imprimir, firmar y enviar por correo postal la transferencia de los derechos de autor